Betamethasone | Diprospan suspension d / in. 2 mg + 5 mg / ml 1 ml ampoules 1 pc.

Latin name

Diprospan

Release form

Suspension for injection.

Packing

1 pc

Indications

Rheumatoid arthritis, extra-articular rheumatism (synovitis, epicondylitis, tendosynovitis, myositis, fibrositis)

Osteoarthritis, traumatic arthritis, osteochondrosis, acute gouty arthritis

Lumbago

Bronchial asthma

Allergic acute and chronic rhinitis

Psoriasis

Keloid scars

Alopecia areata

Contact atopic dermatitis

Nespec.

Contraindications

Peptic ulcer and / or duodenal ulcers

Osteoporosis

Cushing's disease

Diabetes

thrombophlebitis

Viral, fungal, bacterial infections

active form of tuberculosis

Glaucoma

Psychosis

Diverticulitis

State after recent surgery to impose intestinal

anastomosis.

vaccination period. Hypersensitivity to the drug.

Use during pregnancy and lactation

During pregnancy, Diprospan is not used.

If it is necessary to use Diprospan during lactation, breastfeeding is recommended to be stopped.

Composition of

1 ml suspension contains:

Active substances:

Betamethasone dipropionate 6.43 mg

Betamethasone sodium phosphate 2, 63 mg

Excipients:

Anhydrous disubstituted sodium phosphate

Sodium chloride trilon B

Polysorbate 80

Benzyl alcohol

Carboxymethyl cellulose sodium salt

Polyethylene glycol 4000 srdlpr

Dosage and administration

Diprospan® is used for intravenous, intraarticular, periarticular, intra-bursal, intradermal, interstitial and intracranial administration.

The small size of the crystals of betamethasone dipropionate allows the use of needles of small diameter (up to 26 gauge) for intradermal administration and injection directly into the lesion.

The drug is not intended for iv and sc administration.

Injections of the drug Diprospan® should be carried out with strict adherence to asepsis rules.

The dosage regimen and route of administration are set individually, depending on the indications, the severity of the disease and the patient's response.

With systemic use, the initial dose of Diprospan® in most cases is 1-2 ml. Administration is repeated as necessary, depending on the condition of the patient.

Intramuscular administration

Diprospan® should be administered deeply intramuscularly, choosing large muscles and avoiding getting into other tissues (to prevent tissue atrophy).

In severe conditions requiring emergency treatment, the initial dose is 2 ml.

In various dermatological diseases, as a rule, the introduction of 1 ml of a suspension of Diprospan is sufficient.

In diseases of the respiratory system, the onset of the drug occurs within a few hours after the i / m injection of the suspension. With asthma, hay fever, allergic bronchitis and allergic rhinitis, a significant improvement is achieved after the introduction of 1-2 ml of Diprospan.

In acute and chronic bursitis, the initial dose for i / m administration is 1-2 ml of suspension. If necessary, carry out several repeated injections.

If a satisfactory clinical response does not occur after a certain period of time, Diprospan® should be discontinued and another therapy should be prescribed.

Local administration of

With local administration, the simultaneous use of a local anesthetic preparation is necessary only in rare cases. If it is required, then apply 1% or 2% solutions of procaine hydrochloride or lidocaine, not containing methyl paraben, propyl paraben, phenol and other similar substances. In this case, mixing is carried out in a syringe, first collecting the required dose of a suspension of the drug Diprospan® into the syringe from the vial. Then, the required amount of local anesthetic is drawn from the ampoule into the same syringe and shaken for a short time.

In acute bursitis (sub-deltoid, subscapular, ulnar and pre-patellar), the introduction of 1-2 ml of suspension into the synovial bag alleviates pain and restores joint mobility for several hours. After relief of exacerbation in chronic bursitis, lower doses of the drug are used.

In acute tendosynovitis, tendonitis and peritendinitis, one injection of Diprospan® improves the patient's condition in chronic patients - the injection is repeated depending on the patient's response. The introduction of the drug directly into the tendon should be avoided.

Intra-articular administration of the drug Diprospan® in a dose of 0.5-2 ml relieves pain, limiting joint mobility with rheumatoid arthritis and osteoarthritis within 2-4 hours after administration. The duration of the therapeutic effect varies significantly and can be 4 or more weeks.

Recommended doses of the drug when injected into large joints are from 1 to 2 ml in medium joints - 0.5-1 ml in small joints - 0.25-0.5 ml.

In some dermatological diseases, the intradermal administration of the drug Diprospan® directly into the lesion is effective, the dose is 0.2 ml / cm2. The focus is evenly chipped using a tuberculin syringe and a needle with a diameter of about 0.9 mm. The total amount of the drug administered in all areas should not exceed 1 ml for 1 week. For introduction into the lesion, it is recommended to use a tuberculin syringe with a 26 gauge needle.

Recommended single doses of the drug (with an interval between injections of 1 week) with bursitis: with callosity 0.25-0.5 ml (usually 2 injections are effective), with spur - 0.5 ml, with limited mobility of the big toe - 0.5 ml, with synovial cyst - 0.25-0.5 ml, with tendosynovitis - 0.5 ml, with acute gouty arthritis - 0.5-1 ml. For most injections, a tuberculin syringe with a 25 gauge needle is suitable.

After achieving a therapeutic effect, a maintenance dose is selected by gradually reducing the dose of Diprospan®, which is carried out at intervals. The reduction is continued until the minimum effective dose is reached.

If a stressful situation (not related to a disease) occurs or threatens, an increase in the dose of Diprospan® may be required.

Drug withdrawal after prolonged therapy is carried out by gradually reducing the dose.

Monitoring the condition of the patient is carried out at least for a year after the end of long-term therapy or use in high doses.

Side effects

From the central nervous system: sleep disturbances, agitation, depression, anxiety syndrome, polyphagy, neurosis.

From the side of metabolism: weight gain, osteoporosis, growth retardation in children.

Other: secondary infection.



overdose Symptoms: An acute overdose of betamethasone does not lead to life-threatening situations. The introduction of high-dose ACS for several days does not lead to undesirable consequences, except in the case of very high doses or in the case of diabetes mellitus, glaucoma, exacerbation of erosive-ulcerative lesions of the gastrointestinal tract or simultaneous use of digitalis drugs, indirect anticoagulants or potassium excretion diuretics.

Treatment: Careful medical monitoring of the patient's condition is required. Optimal fluid intake and control of plasma and urine electrolytes, especially the ratio of sodium and potassium ions, should be maintained. If necessary, appropriate therapy should be performed.

Storage conditions

The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 25 РC

Do not freeze.

Expiration

2 years.

Deystvuyuschee substances

Betamethasone

Dosage form

dosage form

suspension for injection